Repros Therapeutics (RPRX) Tops Q4 EPS by 1c

Repros Therapeutics (NASDAQ: RPRX) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27).

The Company had cash and cash equivalents of approximately $21.4 million as of December 31, 2015 as compared to $46.6 million as of December 31, 2014. Net cash of approximately $25.3 million was used in operating activities during 2015 as compared to $29.3 million for 2014. The major use of cash for operating activities during 2015 was to fund our clinical development programs and associated administrative costs. No cash was used in investing activities during 2015 and 2014. Cash provided by financing activities during 2015 was $102,000 due to the receipt of $102,000 from a former 10% shareholder to the Company in accordance with Section 16(a) under the Securities Exchange Act of 1934, as amended. Cash provided by financing activities during 2014 was $147,000 due to the exercise of 23,334 stock options for cash.

For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler